Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVSP-BCG in COVID-19 Patients With Controlled Cancers
NCT03305341Phase 1Active, not recruiting
- Start
- May 2025
- Primary completion
- Nov 2026
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1 trial of NVX-CoV2373 and bcg vaccine in coronavirus disease 2019 (COVID-19). Primary endpoints: Number of Participants with Moderate COVID-19 at 28 days, Rate of Positive COVID-19 nucleic acid at 28 days and 3 more. Started May 2025; status: active, not recruiting.
02
Drugs
NVX-CoV2373bcg vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT03305341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03305341.